Comparision of doxorubicin-induced cardiotoxicity in the ICR mice of different sources

Sou Hyun Kim1,*, Keuk-Jun Kim2,#, Joung-Hee Kim2, Jae-Hwan Kwak2, HyunKeun Song3, Joon Young Cho3, Dae Youn Hwang3, Kil Soo Kim3, Young-Suk Jung1,*

1College of Pharmacy, Pusan National University, Busan, Korea
2Department of Biomedical Laboratory Science, Daekyeung College, Gyeongsan, Korea
3College of Pharmacy, Kyungsung University, Busan, Korea
4Department of Microbiology and Immunology, INJE University College of Medicine, Busan, Korea
5Exercise Biochemistry Laboratory, Korea National Sport University, Seoul, Korea
6Department of Biomaterials Science, College of Natural Resources & Life Science/Life and Industry Convergence Research Institute, Pusan National University, Miryang, Korea
7College of Veterinary Medicine, Kyungpook National University, Daegu, Korea

Doxorubicin is a widely used chemotherapeutic agents and is now part of standard therapeutic regimens for a variety of cancers (eg, hematopoietic malignancies and advanced solid tumors of the breast, ovary, thyroid, and bone). However, a potentially lethal and dose-dependent cardiotoxicity that appears within a short time after treatment limits the usage of doxorubicin in cancer patients. Although the mechanism of doxorubicin-induced cardiotoxicity is not completely understood, it is thought that free radical-induced oxidative stress and excessive production of reactive oxygen species are primary drivers of its toxicity. In this study, we compared the doxorubicin-induced cardiotoxicity of ICR mice obtained from three different sources and evaluated the utility of Korl:ICR stock established by the Korean FDA. Because doxorubicin-induced cardiotoxicity is thought to involve the excessive generation of ROS followed by oxidative stress, we determined the representative tissue index of oxidation, lipid peroxidation, and antioxidant, glutathione (GSH), as well as the parameters of heart injury. Doxorubicin treatment successfully induced cardiotoxicity as evidenced by histological examination and serum parameters (eg, levels of LDH and CK activities) in ICR mice. It was accompanied by increased lipid peroxidation and a decrease in both cysteine and GSH, further supporting previous reports that oxidative stress is a potential mechanism of doxorubicin-induced cardiotoxicity. Of interest, we did not observe a significant difference in doxorubicin-induced cardiotoxicity among mice of different origins. Collectively, our results suggest that Korl:ICR strain may be useful in the research of doxorubicin-induced cardiotoxicity.

Keywords: Cardiotoxicity, doxorubicin, oxidative stress, ICR mouse

Received 17 May 2017; Revised version received 5 June 2017; Accepted 7 June 2017

The development of more effective anticancer drugs has greatly increased overall survival and has significantly reduced mortality rates that are accompanied by great benefits relating to patient prognosis. In many cases, a leading cause of morbidity and mortality in patients receiving chemotherapy has been cardiotoxicity. Patients who develop heart failure due to cancer chemotherapy have a 2-year mortality rate of 60% [1]. Consequently, cardiotoxicity caused by chemotherapies has been an area of interest to many clinical researchers [2]. Cardiotoxicity can be indicated by various pathological

*These authors contributed equally to this work.

*Corresponding author: Young-Suk Jung, College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Korea
Tel: +82-51-510-2816; Fax: +82-51-513-6754; E-mail: youngjung@pusan.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
signs such as arrhythmia, changes in blood pressure, myocardial ischemia, or necrosis, but most importantly it can result in heart failure. In general, the onset of cardiac dysfunction is known to occur immediately after the administration of anticancer drugs for up to several years [3,4]. Therefore, animal studies in the preclinical evaluation are essential to assess cardiotoxicity induced by anticancer drugs such as doxorubicin.

Doxorubicin is a widely used chemotherapeutic agent and now part of standard therapeutic regimens for a variety of cancers (eg, hematopoietic malignancies and advanced solid tumors of the breast, ovary, thyroid, and bone) [5]. However, a potentially lethal and dose-dependent cardiotoxicity that appears within a short time after treatment limits the usage of doxorubicin in cancer patients [6,7]. Although the mechanism of doxorubicin-induced cardiotoxicity is not completely understood, it has been considered that free radical-induced oxidative stress and excessive production of reactive oxygen species are primary drivers of its toxicity [8-10]. Recent findings have shown that markedly enhanced electron transfer in the heart following doxorubicin treatment leads to a profound increase in superoxide anion and hydrogen peroxide formation in mitochondria and sarcoplasmic reticulum-two major sites of cardiac injury from doxorubicin [10-13]. Moreover, its cytotoxic potential may be magnified by a high density of mitochondria and lower levels of enzymatic capacity to detoxify ROS [8,9].

Outbred stocks of mice and rats are commonly used in academic and industrial research. ICR mice specifically are a vigorously outbred stock. These mice are Swiss in origin and used as a general-purpose stock and in pharmaceutical research to study genetics, oncology, toxicology, and pharmacology. The ICR mice originated from the albino non-inbred mice in Switzerland, imported to the Rockefeller Institute by Clara J. Lynch in 1926 [14]. They were distributed worldwide and, currently, a number of vendors produce their own commercially available ICR stocks. Therefore, understanding the characteristics of these stocks and their advantages and disadvantages is important as it may help guide experimental design.

In this study, we compared the doxorubicin-induced cardiotoxicity of ICR mice obtained from three different sources and evaluated the utility of Korl:ICR stock established by the Korean FDA. Because doxorubicin-induced cardiotoxicity is suggested to involve the excessive generation of ROS followed by causing oxidative stress, we determined the representative tissue index of oxidation, lipid peroxidation, and antioxidant, glutathione (GSH), as well as the parameters of heart injury.

### Materials and Methods

#### Animals and treatments

Male ICR mice were obtained from three different sources. Korl:ICR were kindly provided by the Department of Laboratory Animal Resources in the National Institute of Food and Drug Safety Evaluation (NIFDS, Cheongju, Korea). The other two groups of ICR stocks were purchased from different vendors located in the United States (referred A: ICR) and Japan (referred B: ICR). The use of animals was in compliance with the guidelines established and approved by the Institutional Animal Care and Use Committee in Pusan National University (PNU-2016-1236). Animals were acclimated to temperature (22±2°C) and humidity (55±5%) controlled rooms with a 12-h light/dark cycle for 1 week prior to use. All mice were provided with ad libitum access to standard irradiated chow diet (Samtako Inc., Osan, Korea) consisting of moisture (12.5%), crude protein (25.43%), crude fat (6.06%), crude fiber (3.9%), crude ash (5.31%), calcium (1.14%), and phosphorus (0.99%) and water. Alterations in body weight were measured using an electronic balance (Mettler Toledo, Greifensee, Switzerland) once a week according to the MFDS guideline. Doxorubicin-treated mice received a single intraperitoneal injection of 20 mg/kg of doxorubicin (Sigma Aldrich, St. Louis, MO, USA) and samples were collected 4 days after doxorubicin administration.

#### Determination of lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB)

A blood sample was collected from the abdominal aorta of each mouse and transferred into a BD Microtainer Blood Collection Tube (BD Life Sciences, Franklin Lakes, NJ, USA).

The samples were centrifuged at 3000 g for 15 min to separate the sera, then stored at −80°C for biochemical analyses. Serum activity of LDH was examined according to the manufacturer’s instructions using commercially available kit obtained from DOGEN (Seoul, Korea). The CK-MB assay kit was purchased from BioVision (San Francisco, CA, USA) and used according to the manufacturer’s instructions. Activities of both LDH and

---

**Lab Anim Res** | June, 2017 | Vol. 33, No. 2
CK-MB were quantified spectrophotometrically at 450 nm using an MULTISKAN GO reader (Thermo Scientific, Waltham, MA, USA).

**Histopathologic evaluation in cardiac tissue**

Tissues were fixed with 4% paraformaldehyde, embedded in paraffin, and sectioned into 5 µm thick slices for histological examination. The paraffin sections were deparaffinized, and subjected to hydrophilic treatment by sequential immersion in a series of 100, 95, 80, and 70% ethanol followed by deionized water. In hematoxylin and eosin (H&E) staining, the nucleus was colored blue with Mayer’s hematoxylin, while the cytoplasm was colored red with eosin (Sigma Aldrich). The stained sections were observed under an inverted microscope (Olympus, Tokyo, Japan).

**Determination of malondialdehyde in the heart**

Hearts were homogenized in a threefold volume of cold 1.15% KCl. An aliquot of lysate was mixed with 0.2% thiobarbituric acid in 2M sodium acetate buffer containing 5% butylated hydroxytoluene. The mixtures were incubated at 95°C for 45 min. The supernatant was injected into HPLC equipped with a fluorescence detector (FLD-3100; Thermo Scientific, Sunnyvale, CA, USA) and a 5 mm Symmetry C18 reversed phase column (4.6 mm×150 mm; Eka Chemicals, Bohus, Sweden). The mobile phase was composed of 35% methanol and 65% sodium phosphate buffer. The complex of MDA-thiobarbituric acid was monitored by fluorescence detection with excitation at 515 nm and emission at 553 nm.

**Measurement of cysteine and glutathione (GSH) in the tissue of heart**

Total cysteine and GSH were analyzed using the sample-derivatization method by 7-benzo-2-oxa-1,3-diazole-4-sulfonic acid (SBD-F) [15]. Hearts were homogenized in a four-fold volume of ice-cold 1 M perchloric acid. The denatured protein was removed by centrifugation at 10,000 g for 10 min and the supernatant was assayed for total cysteine and GSH concentrations using a HPLC separation/fluorometric detection method. 50 mL of N-(2-Mercaptopropionyl) glycine, as an internal standard, was added to 50 mL of samples and briefly mixed. Following the addition of 10 mL of a 10% (w/v) tris(2-carboxyethyl)phosphine hydrochloride solution. Subsequently, 90 mL of trichloroacetic acid solution with 1 mM EDTA was added to each sample and centrifuged (13,000×g, 10 min). The supernatant (50 mL) was then added to another tube containing 10 mL of 1.55 M NaOH, 125 mL of 0.125 M borate buffer (pH 9.5) with 4 mM EDTA, and 50 mL of 0.1% (w/v) SBD-F in borate buffer (0.125 M with 4 mM EDTA). Samples were incubated at 60°C for 1 h, and then, injected into the HPLC with a fluorescence detector (excitation 385 nm and emission 515 nm). The chromatographic separation was performed using a Hector M-C18 column (3 mm×4.6 mm×150 mm) (Chiral Technology Korea, Daejeon, Korea).

**Statistical analysis**

All results are expressed as mean±standard deviation (SD) and analyzed by one-way analysis of variance (ANOVA) followed by Newman-Keuls multiple range test (parametric). The acceptable level of significance was established at P<0.05.

**Results**

**Increased activities of LDH and CK-MB in the serum of doxorubicin-treated ICR mice**

To quantify doxorubicin-induced cardiotoxicity, we examined the serum markers, LDH and CK-MB, for myocardial injury. Both LDH (Figure 1A) and CK-MB (Figure 1B) were significantly elevated in the doxorubicin-treated mice as compared with corresponding control mice. The levels of LDH and CK in doxorubicin-treated mice were not significantly different between the three different sources of mice.

**Histopathological changes in the heart of doxorubicin-treated ICR mice**

In line with serum parameters of doxorubicin-treated mice, examinations of heart sections using light microscopy 96 h after doxorubicin treatment revealed loss of myofibril and striations, as well as cytoplasmic vacuolization as shown by H&E staining in Figure 2B, 2D, 2F compared with corresponding control (Figure 2A, 2C, 2E). There was no significant difference in the comparison of the three different sources.

**Increased lipid peroxidation in the heart of doxorubicin-treated ICR mice**

Oxidative stress is considered to be the major cause of cardiotoxicity induced by doxorubicin and the accumulation
of doxorubicin-induced reactive oxygen species in the heart may explain the cardiac lipid membrane peroxidation [16]. Thus, we further assessed lipid peroxidation in the heart using MDA levels. Figure 3 shows the effect of the doxorubicin treatment on the levels of MDA in the heart homogenates. Acute treatment of doxorubicin in the mice of three different sources dramatically increased MDA levels with no significant difference among sources observed.

**Decreased levels of cysteine and GSH in the hearts of doxorubicin-treated ICR mice**

GSH is the most abundant endogenous antioxidant and has a potential role defending against oxidative stress through its electrophilic-scavenging ability [17]. Thus it is considered that GSH level is an important determinant of antioxidant capacity in the tissue. Its biosynthesis is tightly regulated by the availability of substrate, cysteine, as well as the activity of g-glutamylcysteine ligase, a rate-limiting enzyme in the synthesis of GSH [18].

It has been suggested that the generation of oxygen radicals by doxorubicin-related redox cycle could explain...
depleted GSH pools in the heart that have been found after doxorubicin administration [19,20]. Figure 4 shows that doxorubicin treatment significantly reduced the cysteine concentration (Figure 4A) and was accompanied by a decrease in levels of GSH (Figure 4B) in the heart, suggesting that low levels of GSH contributed partially to decrease in the ability to defense oxidative stress followed by enhancement of lipid peroxidation.

Discussion

Experimental animal models have been widely used to study pathogenesis of human disease or to test the efficacy of potential therapeutic interventions. Moreover, such models have been adopted to determine toxicity and to explore the underlying molecular mechanisms of various diseases and conditions.

There are several reasons why toxicologists have been reluctant to use non-classical animal models in drug safety assessments. Firstly, an ideal animal model is one that closely imitates a human disease mechanistically, etiologically and pathologically-conditions that are not always met. Furthermore, incorporating a new animal model into an existing test system might produce new and unexpected results that do not accurately reflect the human phenomenon. Preclinical safety studies aim to examine dose-dependent risks of potential drug candidates, and to identify target organ toxicity and type of toxicity. These studies are usually carried out in highly standardized and well-characterized laboratory animals. Although animal models do not imitate human disease conditions in all respects, they have proven to be of value because there are clear limits and simplifications that correspond to the nature of the model.

The ICR stock, named “Korl:ICR” has been established and used for the last 50 years in the National Institute of Food and Drug Safety Evaluation (NIFDS) in Korea. Recently, it was proved that Korl:ICR is a genetically independent stock compared with other ICR stocks originated for Japan and USA, however, no biological differences have been observed [21]. In line with this, the purpose of present study was to characterize the Korl:ICR stock in terms of cardiotoxicity and determine its utility in evaluating the safety of preclinical drug candidates.

Of outbred mouse stocks, ICR has been often employed in cardiotoxicity research and it has been considered a good model of doxorubicin-induced cardiotoxicity to investigate its toxic mechanism and test the preventive effect of some compounds [22-24]. Moreover, Ma et al. [25] suggested that ICR mice are more appropriate than inbred strain C57BL/6J which is highly susceptible and variable to large doses of doxorubicin in acute cardiotoxicity induced by doxorubicin.

There is increasing experimental evidence suggesting that the life-threatening effects of doxorubicin on the heart result from drug-induced, oxidative tissue injury [26,27]. Doxorubicin-related reactive oxygen metabolism may overwhelm the limited capacity of heart to detoxify free radicals, resulting in extensive oxidative damage to myocardial cells [28]. In this study, doxorubicin treatment successfully induced cardiotoxicity as evidenced by histological examination and serum parameters (ie, LDH and CK-MB activities) in ICR mice. These effects were accompanied by increased lipid peroxidation and decreases in both cysteine and GSH, supporting previous reports that oxidative stress is potential mechanism of doxorubicin-induced cardiotoxicity. Of interest, we did
not observe differences in doxorubicin-induced cardiotoxicity depending on the origin of the mice. Collectively, our results suggest that Korl:ICR stock may at least be useful in the research of doxorubicin-induced cardiotoxicity.

Acknowledgments

This project was supported by a grant of BIOREIN (Laboratory Animal Bio Resources Initiative) from Ministry of Food and Drug Safety in 2016.

Conflict of interests The authors declare that there is no financial conflict of interests to publish these results.

References

1. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echo-cardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014; 63(25): 2751-2768.
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56(2): 185-229.
3. Perrino C, Schiattarella GG, Magliulo F, Ilardi F, Carotenuto G, Gargiulo G, Serino F, Ferrone M, Scudiero F, Carbone A, Trimarco B, Esposito G. Cardiace side effects of chemotherapy: state of art and strategies for a correct management. Curr Vasc Pharmacol 2014; 12(1): 106-116.
4. Raschi E, Vasina V, Ursina MG, Boriani G, Martoni A, De Ponti F. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010; 125(2): 196-218.
5. Carter SK. Adriamycin-Review. J Natl Cancer Inst 1975; 55(6): 1265-1274.
6. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin Cardiomyopathy-Evaluation by Phonoangiography, Endomyocardial Biopsy, and Cardiac-Catheterization. Ann Intern Med 1978; 88(2): 168-175.
7. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early Anthracycline Cardiotoxicity. Am J Med 1978; 65(5): 823-832.
8. Maksimenko AV, Vavaev AS. Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological development. Antioxidants & Redox Signaling 2013; 18(8): 899-929.
9. Thayer WS. Adriamycin Stimulated Superoxide Formation in Sub-Mitochondrial Particles. Chem Biol Interact 1977; 19(3): 265-278.
10. Doroshow JH, Reeves J. Anthracycline-Enhanced Oxygen Radical Formation in the Heart. in: Proc Am Assoc Canc Res 1980; 21: 266.
11. Carvalho FS, Beurgo G, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 2014; 34(1): 106-135.
12. Chia R, Achilli F, Festing MF, Fisher EM. The origins and uses of mouse outbred stocks. Nat Genet 2005; 37(11): 1181-1186.
13. Lu SC. Glutathione synthesis. Biochim Biophys Acta 2013; 1830(5): 3143-3153.
14. Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, Chua BH, Melatonin as an effective protector against doxorubicin-induced oxidative stress. Int J Mol Sci 2014; 15(11): 22636-22654.
15. Ma Y, Zhang X, Bao H, Mi S, Cai W, Yan H, Wang Q, Wang Z, Yan J, Fan GC et al. Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One 2012; 7(7): e40763.
16. Thayer WS. Adriamycin stimulated superoxide formation in submitochondrial particles. Chem Biol Interact 1977; 19(3): 265-278.
17. Doroshow JH, Lockey T, Delongchamp RR, Dhakal I, Makhoul M, Gersl V, Simunek T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxidants & Redox Signaling 2013; 18(8): 899-929.
18. Sou Hyun Kim et al.